Cadrenal Therapeutics, Inc. entered into a securities purchase agreement on June 30, 2026, to conduct a private placement with an institutional investor. The company issued pre-funded warrants, Series C-1 warrants, and Series C-2 warrants to purchase a total of 2,880,000 shares of common stock, including placement agent warrants. The combined purchase price for the pre-funded and common warrants was $3.1249 per unit, generating approximately $3.0 million in gross proceeds. The company intends to use the net proceeds for working capital. Directors and officers entered into 60-day lock-up agreements. Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders.
